<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02248597</url>
  </required_header>
  <id_info>
    <org_study_id>CCCWFU 97214</org_study_id>
    <secondary_id>NCI-2014-01898</secondary_id>
    <secondary_id>CCCWFU 97214</secondary_id>
    <secondary_id>P30CA012197</secondary_id>
    <nct_id>NCT02248597</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases</brief_title>
  <official_title>Haploidentical Stem Cell Transplant Using Post Transplant Cyclophosphamide for GvHD Prophylaxis: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies donor stem cell transplant followed by cyclophosphamide in
      treating patients with hematological diseases. Giving chemotherapy before a donor stem cell
      transplant helps stop the growth of cells in the bone marrow, including normal blood-forming
      cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused
      into the patient they may help the patient's bone marrow make stem cells, red blood cells,
      white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an
      immune response against the body's normal cells (called graft-versus-host disease). Giving
      cyclophosphamide after the transplant may stop this from happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if haploidentical stem cell transplant using post-transplant cyclophosphamide
      results in 60% or better disease free survival (DFS) at 12 months at our institution.

      SECONDARY OBJECTIVES:

      I. To determine the rate of acute and chronic graft-versus-host disease (GvHD), non-relapse
      mortality, and relapse.

      OUTLINE:

      PREPARATIVE REGIMEN: Patients receive fludarabine phosphate intravenously (IV) once daily
      (QD) on days -6 to -2. Patients receiving myeloablative conditioning receive busulfan IV
      every 6 hours for 16 doses on days -7 to -4 and patients receiving reduced intensity
      conditioning receive busulfan IV every 6 hours for 8 doses on days -5 to -4. Patients also
      receive cyclophosphamide IV QD on days -3 and -2

      TRANSPLANT: Patients undergo stem cell transplant on day 0.

      GVHD PROPHYLAXIS: Patients receive cyclophosphamide QD on days 3 and 4, tacrolimus on days
      5-180, and mycophenolate mofetil on days 5-35.

      After completion of study treatment, patients are followed up periodically for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12 month disease free survival probability</measure>
    <time_frame>At 12 months</time_frame>
    <description>The proportion of patients who experience death or disease relapse by one year will be calculated and a corresponding 95% confidence interval will be constructed using the normal approximation for binomial proportions. The survival function will be estimated and plotted using the method of Kaplan and Meier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of acute GvHD</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of chronic GvHD</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse (or death)</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free mortality</measure>
    <time_frame>At 12 months</time_frame>
    <description>The cumulative incidence function in the presence of relapse will be estimated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Hematopoietic/Lymphoid Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (stem cell transplant with GVHD prophylaxis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV QD on days -6 to -2. Patients receiving myeloablative conditioning receive busulfan IV every 6 hours for 16 doses on days -7 to -4 and patients receiving reduced intensity conditioning receive busulfan IV every 6 hours for 8 doses on days -5 to -4. Patients also receive cyclophosphamide IV QD on days -3 and -2
TRANSPLANT: Patients undergo stem cell transplant on day 0.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide QD on days 3 and 4, tacrolimus on days 5-180, and mycophenolate mofetil on days 5-35. Allogeneic hematopoietic stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (stem cell transplant with GVHD prophylaxis)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (stem cell transplant with GVHD prophylaxis)</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (stem cell transplant with GVHD prophylaxis)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo myeloablative or reduced intensity allogeneic stem cell transplant</description>
    <arm_group_label>Treatment (stem cell transplant with GVHD prophylaxis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <arm_group_label>Treatment (stem cell transplant with GVHD prophylaxis)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <arm_group_label>Treatment (stem cell transplant with GVHD prophylaxis)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a hematological malignancy requiring an allogeneic stem cell transplant
             consistent with the standard of care

          -  Hematologic remission of disease

          -  Lack of 8 out of 8 human leukocyte antigen (HLA) loci-matched related donor or
             HLA-matched unrelated donor

          -  Available familial haploidentical (4 to 7 out of 8 HLA loci-matched) donor

        Exclusion Criteria:

          -  Significant organ dysfunction &gt; grade 3 by Common Terminology Criteria for Adverse
             Events (CTCAE), and a left ventricular ejection fraction &lt; 40% (evaluated by
             echocardiogram) or &lt; 30% (evaluated by magnetic resonance imaging [MRI]) within the
             first 30 days after stem cell transplant (SCT)

          -  Human immunodeficiency virus (HIV) positive (recipients who are positive for hepatitis
             B [hepatitis B virus (HBV)], hepatitis C [hepatitis C virus (HCV)] or human T-cell
             lymphotropic virus [HTLV-]I/II are not excluded from participation)

          -  Positive pregnancy test for women of childbearing age

          -  Estimated probability of surviving less than 3 months

          -  Major anticipated illness or organ failure incompatible with survival form transplant

          -  Severe psychiatric illness or mental deficiency sufficiently severe as to make
             compliance with the transplant treatment unlikely and informed consent impossible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachariah McIver</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center of Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zachariah A. McIver</last_name>
      <phone>336-713-5440</phone>
      <email>zmciver@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Zachariah A. McIver</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>September 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

